|
Malignant neoplasm of larynx
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we aimed to investigate the effects of expression of the FGFR family members FGFR1 and FGFR3, as well as their downstream PI3K/AKT signal-regulated kinases, on the aggressiveness and prognosis of laryngeal cancer.
|
29299828 |
2018 |
|
Developmental Disabilities
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Receptor tyrosine kinase FGFR3 is involved in many signaling networks and is frequently mutated in developmental disorders and cancer.
|
29478821 |
2018 |
|
Mental Depression
|
0.010 |
Biomarker
|
disease |
BEFREE |
Increased cholinergic signalling in hippocampus also increases behaviours related to anxiety and depression in mice, which can be reversed by ACh receptor antagonists.
|
28264149 |
2018 |
|
Depressive disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Increased cholinergic signalling in hippocampus also increases behaviours related to anxiety and depression in mice, which can be reversed by ACh receptor antagonists.
|
28264149 |
2018 |
|
Liver diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We describe FGFR3 overexpression in 15% of CRC patients with oligometastatic liver disease as a prognosticator for poor outcome.
|
30181810 |
2018 |
|
Musculoskeletal Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
These orthopedic disorders are known to have genetic changes in FGFR3.
|
29068064 |
2018 |
|
Odontogenic Tumors
|
0.010 |
Biomarker
|
group |
BEFREE |
Crouzon syndrome with acanthosis nigricans (CAN) is caused by a mutation in the fibroblast growth factor receptor ( FGFR) 3 gene that presents clinically as Crouzonoid craniofacial features in association with other anomalies such as acanthosis nigricans and benign odontogenic tumors.
|
29351036 |
2018 |
|
Schizophrenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Positive allosteric modulators (PAMs) that target the M<sub>1</sub> muscarinic acetylcholine (ACh) receptor (M<sub>1</sub> mAChR) are potential treatments for cognitive deficits in conditions such as Alzheimer disease and schizophrenia.
|
29691279 |
2018 |
|
Osteochondropathy
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The aim of this study was to investigate FGF8 and FGFR3 expression in clinical samples of Kashin-Beck disease (KBD), an endemic osteochondropathy found in China, as well as in pre-clinical models of this disease.
|
29626475 |
2018 |
|
Hemangioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, VHL-related HBs displayed increased fibroblast growth factor receptor 3 (FGFR3) protein expression when compared to VHL-related ccRCCs.
|
29805741 |
2018 |
|
Laryngeal Squamous Cell Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Mutations in PIK3CA and FGFR3 were detected in PD and LSCC cases, as well as other HNSCC cases, but absent in NPD cases.
|
29700339 |
2018 |
|
Depressed mood
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Increased cholinergic signalling in hippocampus also increases behaviours related to anxiety and depression in mice, which can be reversed by ACh receptor antagonists.
|
28264149 |
2018 |
|
Carcinoma of larynx
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we aimed to investigate the effects of expression of the FGFR family members FGFR1 and FGFR3, as well as their downstream PI3K/AKT signal-regulated kinases, on the aggressiveness and prognosis of laryngeal cancer.
|
29299828 |
2018 |
|
Lafora Disease
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Further examination using neuron-specific methylome analysis revealed that the gene body of FGFR3 was hypermethylated in LBD, suggesting its increased transcription.
|
29909202 |
2018 |
|
Lewy Body Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Methylation changes and aberrant expression of FGFR3 in Lewy body disease neurons.
|
29909202 |
2018 |
|
Papillary transitional cell neoplasm of low malignant potential
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
FGFR3 mutations were observed more frequently in PUNLMP and low-grade NIPUC than in inverted papillomas (P = 0.009), whereas the opposite trend was noted for HRAS mutations (P < 0.001).
|
29193225 |
2018 |
|
orthopedic disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
These orthopedic disorders are known to have genetic changes in FGFR3.
|
29068064 |
2018 |
|
Kashin-Beck Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
FGF8 and FGFR3 may therefore play an important role in the onset of deep zone necrosis and pathogenesis in KBD in adolescent children.
|
29626475 |
2018 |
|
Ciliopathies
|
0.010 |
Biomarker
|
disease |
BEFREE |
Regulation of ciliary function by fibroblast growth factor signaling identifies FGFR3-related disorders achondroplasia and thanatophoric dysplasia as ciliopathies.
|
29360984 |
2018 |
|
Aortic Valve Insufficiency
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
There were significant differences in ACH and AEH between the groups (control vs VSD with ACP vs VSD with ACP and AR, median ACH [%], 35.1 vs 32.0 vs 22.1; median AEH [%], 52.0 vs 48.0 vs 34.4, respectively; P < 0.01]).
|
28108755 |
2017 |
|
Astrocytoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moderate to strong FGFR3 staining was detected in gliomas of all grades, was more common in females, and was associated with poor survival in diffuse astrocytomas.
|
28379477 |
2017 |
|
Fuchs Endothelial Dystrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Higher percentages of stromal cells in FECD versus normal stained for αSMA (OR = 864.26, P < 0.001), brain-derived neurotrophic factor (BDNF, OR = 6.34, P = 0.005), fibroblast growth factor 7 (FGF-7, OR = 2.76, P = 0.011), FGF-9 (OR = 5.97, P < 0.001), receptor FGFR-3 (OR = 13.90, P = < 0.001), and serum amyloid A1 (OR = 3.45, P = 0.023).
|
28481834 |
2017 |
|
Headache
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Parasympathetic innervation of meninges and ability of carbachol, acetylcholine (ACh) receptor (AChR) agonist, to induce headaches suggests contribution of cholinergic mechanisms to primary headaches.
|
28496430 |
2017 |
|
Ventricular Septal Defects
|
0.010 |
GeneticVariation
|
group |
BEFREE |
There were significant differences in ACH and AEH between the groups (control vs VSD with ACP vs VSD with ACP and AR, median ACH [%], 35.1 vs 32.0 vs 22.1; median AEH [%], 52.0 vs 48.0 vs 34.4, respectively; P < 0.01]).
|
28108755 |
2017 |
|
Hypophosphatasia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, we describe a unique case with monoallelic FGFR3 and biallelic ALPL mutations leading to features of both hypochondroplasia and hypophosphatasia.
|
28763161 |
2017 |